nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—ORM1—Erlotinib—pancreatic cancer	0.144	0.184	CbGbCtD
Mirabegron—BCHE—Irinotecan—pancreatic cancer	0.112	0.144	CbGbCtD
Mirabegron—ALB—Erlotinib—pancreatic cancer	0.0604	0.0772	CbGbCtD
Mirabegron—ALB—Irinotecan—pancreatic cancer	0.0545	0.0698	CbGbCtD
Mirabegron—ALB—Fluorouracil—pancreatic cancer	0.0523	0.0669	CbGbCtD
Mirabegron—ABCB1—Tamoxifen—pancreatic cancer	0.0371	0.0475	CbGbCtD
Mirabegron—CYP2D6—Tamoxifen—pancreatic cancer	0.035	0.0448	CbGbCtD
Mirabegron—ABCB1—Gemcitabine—pancreatic cancer	0.032	0.0409	CbGbCtD
Mirabegron—ABCB1—Erlotinib—pancreatic cancer	0.0316	0.0404	CbGbCtD
Mirabegron—CYP2D6—Erlotinib—pancreatic cancer	0.0298	0.0381	CbGbCtD
Mirabegron—ABCB1—Irinotecan—pancreatic cancer	0.0285	0.0365	CbGbCtD
Mirabegron—CYP3A4—Tamoxifen—pancreatic cancer	0.0223	0.0285	CbGbCtD
Mirabegron—ABCB1—Docetaxel—pancreatic cancer	0.0209	0.0267	CbGbCtD
Mirabegron—ABCB1—Sunitinib—pancreatic cancer	0.0208	0.0266	CbGbCtD
Mirabegron—CYP3A4—Erlotinib—pancreatic cancer	0.0189	0.0242	CbGbCtD
Mirabegron—CYP3A4—Irinotecan—pancreatic cancer	0.0171	0.0219	CbGbCtD
Mirabegron—ABCB1—Doxorubicin—pancreatic cancer	0.0156	0.0199	CbGbCtD
Mirabegron—CYP2D6—Doxorubicin—pancreatic cancer	0.0147	0.0188	CbGbCtD
Mirabegron—CYP3A4—Docetaxel—pancreatic cancer	0.0125	0.016	CbGbCtD
Mirabegron—CYP3A4—Sunitinib—pancreatic cancer	0.0125	0.0159	CbGbCtD
Mirabegron—CYP3A4—Doxorubicin—pancreatic cancer	0.00934	0.0119	CbGbCtD
Mirabegron—ORM1—bile—pancreatic cancer	0.000756	0.527	CbGeAlD
Mirabegron—Musculoskeletal discomfort—Tamoxifen—pancreatic cancer	0.000594	0.00295	CcSEcCtD
Mirabegron—Hypertension—Sunitinib—pancreatic cancer	0.000591	0.00294	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Erlotinib—pancreatic cancer	0.000588	0.00292	CcSEcCtD
Mirabegron—Cystitis noninfective—Epirubicin—pancreatic cancer	0.000588	0.00292	CcSEcCtD
Mirabegron—Cardiac disorder—Gemcitabine—pancreatic cancer	0.000586	0.00291	CcSEcCtD
Mirabegron—Breast disorder—Docetaxel—pancreatic cancer	0.000585	0.00291	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Docetaxel—pancreatic cancer	0.000583	0.0029	CcSEcCtD
Mirabegron—Arthralgia—Sunitinib—pancreatic cancer	0.000583	0.0029	CcSEcCtD
Mirabegron—Cystitis—Epirubicin—pancreatic cancer	0.000581	0.00289	CcSEcCtD
Mirabegron—Nasopharyngitis—Docetaxel—pancreatic cancer	0.000579	0.00288	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.000579	0.00288	CcSEcCtD
Mirabegron—Dyspepsia—Tamoxifen—pancreatic cancer	0.000574	0.00285	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Docetaxel—pancreatic cancer	0.000571	0.00284	CcSEcCtD
Mirabegron—Dry mouth—Sunitinib—pancreatic cancer	0.00057	0.00283	CcSEcCtD
Mirabegron—Dyspepsia—Erlotinib—pancreatic cancer	0.000568	0.00282	CcSEcCtD
Mirabegron—Vaginal infection—Epirubicin—pancreatic cancer	0.000568	0.00282	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.000563	0.0028	CcSEcCtD
Mirabegron—Fatigue—Tamoxifen—pancreatic cancer	0.000562	0.00279	CcSEcCtD
Mirabegron—Constipation—Tamoxifen—pancreatic cancer	0.000558	0.00277	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.000557	0.00277	CcSEcCtD
Mirabegron—Fatigue—Erlotinib—pancreatic cancer	0.000556	0.00276	CcSEcCtD
Mirabegron—Dry eye—Epirubicin—pancreatic cancer	0.000556	0.00276	CcSEcCtD
Mirabegron—Infection—Sunitinib—pancreatic cancer	0.000555	0.00276	CcSEcCtD
Mirabegron—Constipation—Erlotinib—pancreatic cancer	0.000552	0.00274	CcSEcCtD
Mirabegron—Back pain—Irinotecan—pancreatic cancer	0.000545	0.00271	CcSEcCtD
Mirabegron—Neoplasm—Epirubicin—pancreatic cancer	0.000544	0.0027	CcSEcCtD
Mirabegron—Bladder pain—Epirubicin—pancreatic cancer	0.000544	0.0027	CcSEcCtD
Mirabegron—Cystitis noninfective—Doxorubicin—pancreatic cancer	0.000544	0.0027	CcSEcCtD
Mirabegron—Skin disorder—Sunitinib—pancreatic cancer	0.000543	0.0027	CcSEcCtD
Mirabegron—Cystitis—Doxorubicin—pancreatic cancer	0.000537	0.00267	CcSEcCtD
Mirabegron—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.000533	0.00265	CcSEcCtD
Mirabegron—Back pain—Gemcitabine—pancreatic cancer	0.000531	0.00264	CcSEcCtD
Mirabegron—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.000528	0.00262	CcSEcCtD
Mirabegron—Vaginal infection—Doxorubicin—pancreatic cancer	0.000525	0.00261	CcSEcCtD
Mirabegron—Urticaria—Tamoxifen—pancreatic cancer	0.000518	0.00258	CcSEcCtD
Mirabegron—Abdominal pain—Tamoxifen—pancreatic cancer	0.000516	0.00256	CcSEcCtD
Mirabegron—Dry eye—Doxorubicin—pancreatic cancer	0.000514	0.00255	CcSEcCtD
Mirabegron—Abdominal pain—Erlotinib—pancreatic cancer	0.00051	0.00254	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000509	0.00253	CcSEcCtD
Mirabegron—Vision blurred—Fluorouracil—pancreatic cancer	0.000509	0.00253	CcSEcCtD
Mirabegron—Neoplasm—Doxorubicin—pancreatic cancer	0.000503	0.0025	CcSEcCtD
Mirabegron—Bladder pain—Doxorubicin—pancreatic cancer	0.000503	0.0025	CcSEcCtD
Mirabegron—Infestation NOS—Docetaxel—pancreatic cancer	0.000499	0.00248	CcSEcCtD
Mirabegron—Infestation—Docetaxel—pancreatic cancer	0.000499	0.00248	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Docetaxel—pancreatic cancer	0.000495	0.00246	CcSEcCtD
Mirabegron—Dyspepsia—Sunitinib—pancreatic cancer	0.000492	0.00244	CcSEcCtD
Mirabegron—Vascular purpura—Epirubicin—pancreatic cancer	0.000488	0.00243	CcSEcCtD
Mirabegron—Hypertension—Irinotecan—pancreatic cancer	0.000487	0.00242	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000482	0.0024	CcSEcCtD
Mirabegron—Fatigue—Sunitinib—pancreatic cancer	0.000482	0.00239	CcSEcCtD
Mirabegron—Constipation—Sunitinib—pancreatic cancer	0.000478	0.00237	CcSEcCtD
Mirabegron—Hypertension—Gemcitabine—pancreatic cancer	0.000474	0.00236	CcSEcCtD
Mirabegron—Asthenia—Tamoxifen—pancreatic cancer	0.000468	0.00233	CcSEcCtD
Mirabegron—Arthralgia—Gemcitabine—pancreatic cancer	0.000468	0.00232	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000464	0.00231	CcSEcCtD
Mirabegron—Asthenia—Erlotinib—pancreatic cancer	0.000463	0.0023	CcSEcCtD
Mirabegron—Pruritus—Tamoxifen—pancreatic cancer	0.000462	0.00229	CcSEcCtD
Mirabegron—Infection—Irinotecan—pancreatic cancer	0.000457	0.00227	CcSEcCtD
Mirabegron—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000457	0.00227	CcSEcCtD
Mirabegron—Pruritus—Erlotinib—pancreatic cancer	0.000457	0.00227	CcSEcCtD
Mirabegron—Purpura—Epirubicin—pancreatic cancer	0.000453	0.00225	CcSEcCtD
Mirabegron—Vascular purpura—Doxorubicin—pancreatic cancer	0.000452	0.00224	CcSEcCtD
Mirabegron—Rhinitis—Docetaxel—pancreatic cancer	0.000449	0.00223	CcSEcCtD
Mirabegron—Diarrhoea—Tamoxifen—pancreatic cancer	0.000446	0.00222	CcSEcCtD
Mirabegron—Cerebrovascular accident—Epirubicin—pancreatic cancer	0.000446	0.00221	CcSEcCtD
Mirabegron—Infection—Gemcitabine—pancreatic cancer	0.000445	0.00221	CcSEcCtD
Mirabegron—Urinary tract disorder—Docetaxel—pancreatic cancer	0.000442	0.0022	CcSEcCtD
Mirabegron—Abdominal pain—Sunitinib—pancreatic cancer	0.000442	0.00219	CcSEcCtD
Mirabegron—Diarrhoea—Erlotinib—pancreatic cancer	0.000442	0.00219	CcSEcCtD
Mirabegron—Connective tissue disorder—Docetaxel—pancreatic cancer	0.00044	0.00219	CcSEcCtD
Mirabegron—Urethral disorder—Docetaxel—pancreatic cancer	0.000439	0.00218	CcSEcCtD
Mirabegron—Infection—Fluorouracil—pancreatic cancer	0.000438	0.00218	CcSEcCtD
Mirabegron—Osteoarthritis—Epirubicin—pancreatic cancer	0.000437	0.00217	CcSEcCtD
Mirabegron—Skin disorder—Gemcitabine—pancreatic cancer	0.000435	0.00216	CcSEcCtD
Mirabegron—Dizziness—Tamoxifen—pancreatic cancer	0.000431	0.00214	CcSEcCtD
Mirabegron—Tachycardia—Fluorouracil—pancreatic cancer	0.00043	0.00214	CcSEcCtD
Mirabegron—Dizziness—Erlotinib—pancreatic cancer	0.000427	0.00212	CcSEcCtD
Mirabegron—Erythema multiforme—Docetaxel—pancreatic cancer	0.000423	0.0021	CcSEcCtD
Mirabegron—Purpura—Doxorubicin—pancreatic cancer	0.000419	0.00208	CcSEcCtD
Mirabegron—Eye disorder—Docetaxel—pancreatic cancer	0.000419	0.00208	CcSEcCtD
Mirabegron—Cardiac disorder—Docetaxel—pancreatic cancer	0.000416	0.00207	CcSEcCtD
Mirabegron—Cerebrovascular accident—Doxorubicin—pancreatic cancer	0.000412	0.00205	CcSEcCtD
Mirabegron—Rash—Tamoxifen—pancreatic cancer	0.000411	0.00204	CcSEcCtD
Mirabegron—Dermatitis—Tamoxifen—pancreatic cancer	0.000411	0.00204	CcSEcCtD
Mirabegron—Headache—Tamoxifen—pancreatic cancer	0.000409	0.00203	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000408	0.00203	CcSEcCtD
Mirabegron—Rash—Erlotinib—pancreatic cancer	0.000407	0.00202	CcSEcCtD
Mirabegron—Dermatitis—Erlotinib—pancreatic cancer	0.000407	0.00202	CcSEcCtD
Mirabegron—Dyspepsia—Irinotecan—pancreatic cancer	0.000405	0.00201	CcSEcCtD
Mirabegron—Headache—Erlotinib—pancreatic cancer	0.000404	0.00201	CcSEcCtD
Mirabegron—Osteoarthritis—Doxorubicin—pancreatic cancer	0.000404	0.00201	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000402	0.002	CcSEcCtD
Mirabegron—Asthenia—Sunitinib—pancreatic cancer	0.000401	0.00199	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000397	0.00197	CcSEcCtD
Mirabegron—Fatigue—Irinotecan—pancreatic cancer	0.000397	0.00197	CcSEcCtD
Mirabegron—Pruritus—Sunitinib—pancreatic cancer	0.000395	0.00196	CcSEcCtD
Mirabegron—Breast disorder—Epirubicin—pancreatic cancer	0.000395	0.00196	CcSEcCtD
Mirabegron—Constipation—Irinotecan—pancreatic cancer	0.000394	0.00196	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000393	0.00195	CcSEcCtD
Mirabegron—Nasopharyngitis—Epirubicin—pancreatic cancer	0.00039	0.00194	CcSEcCtD
Mirabegron—Dyspepsia—Fluorouracil—pancreatic cancer	0.000388	0.00193	CcSEcCtD
Mirabegron—Nausea—Tamoxifen—pancreatic cancer	0.000387	0.00193	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000387	0.00192	CcSEcCtD
Mirabegron—Fatigue—Gemcitabine—pancreatic cancer	0.000387	0.00192	CcSEcCtD
Mirabegron—Gastritis—Epirubicin—pancreatic cancer	0.000386	0.00192	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.000385	0.00191	CcSEcCtD
Mirabegron—Constipation—Gemcitabine—pancreatic cancer	0.000383	0.0019	CcSEcCtD
Mirabegron—Nausea—Erlotinib—pancreatic cancer	0.000383	0.0019	CcSEcCtD
Mirabegron—Diarrhoea—Sunitinib—pancreatic cancer	0.000382	0.0019	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000381	0.00189	CcSEcCtD
Mirabegron—Abdominal distension—Epirubicin—pancreatic cancer	0.00038	0.00189	CcSEcCtD
Mirabegron—Influenza—Epirubicin—pancreatic cancer	0.000377	0.00188	CcSEcCtD
Mirabegron—Back pain—Docetaxel—pancreatic cancer	0.000377	0.00187	CcSEcCtD
Mirabegron—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000376	0.00187	CcSEcCtD
Mirabegron—Dizziness—Sunitinib—pancreatic cancer	0.000369	0.00184	CcSEcCtD
Mirabegron—Breast disorder—Doxorubicin—pancreatic cancer	0.000365	0.00181	CcSEcCtD
Mirabegron—Abdominal pain—Irinotecan—pancreatic cancer	0.000364	0.00181	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000364	0.00181	CcSEcCtD
Mirabegron—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000361	0.0018	CcSEcCtD
Mirabegron—Gastritis—Doxorubicin—pancreatic cancer	0.000358	0.00178	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000356	0.00177	CcSEcCtD
Mirabegron—Rash—Sunitinib—pancreatic cancer	0.000352	0.00175	CcSEcCtD
Mirabegron—Dermatitis—Sunitinib—pancreatic cancer	0.000352	0.00175	CcSEcCtD
Mirabegron—Abdominal distension—Doxorubicin—pancreatic cancer	0.000352	0.00175	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000351	0.00174	CcSEcCtD
Mirabegron—Urticaria—Fluorouracil—pancreatic cancer	0.00035	0.00174	CcSEcCtD
Mirabegron—Headache—Sunitinib—pancreatic cancer	0.00035	0.00174	CcSEcCtD
Mirabegron—Influenza—Doxorubicin—pancreatic cancer	0.000349	0.00173	CcSEcCtD
Mirabegron—Palpitations—Docetaxel—pancreatic cancer	0.000345	0.00171	CcSEcCtD
Mirabegron—Hypertension—Docetaxel—pancreatic cancer	0.000337	0.00167	CcSEcCtD
Mirabegron—Infestation NOS—Epirubicin—pancreatic cancer	0.000336	0.00167	CcSEcCtD
Mirabegron—Infestation—Epirubicin—pancreatic cancer	0.000336	0.00167	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000334	0.00166	CcSEcCtD
Mirabegron—Arthralgia—Docetaxel—pancreatic cancer	0.000332	0.00165	CcSEcCtD
Mirabegron—Nausea—Sunitinib—pancreatic cancer	0.000332	0.00165	CcSEcCtD
Mirabegron—Asthenia—Irinotecan—pancreatic cancer	0.00033	0.00164	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.00033	0.00164	CcSEcCtD
Mirabegron—Urinary tract infection—Epirubicin—pancreatic cancer	0.000327	0.00163	CcSEcCtD
Mirabegron—Dry mouth—Docetaxel—pancreatic cancer	0.000325	0.00161	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000325	0.00161	CcSEcCtD
Mirabegron—Asthenia—Gemcitabine—pancreatic cancer	0.000322	0.0016	CcSEcCtD
Mirabegron—Pruritus—Gemcitabine—pancreatic cancer	0.000317	0.00158	CcSEcCtD
Mirabegron—Infection—Docetaxel—pancreatic cancer	0.000316	0.00157	CcSEcCtD
Mirabegron—Sinusitis—Epirubicin—pancreatic cancer	0.000316	0.00157	CcSEcCtD
Mirabegron—Diarrhoea—Irinotecan—pancreatic cancer	0.000315	0.00156	CcSEcCtD
Mirabegron—Pruritus—Fluorouracil—pancreatic cancer	0.000312	0.00155	CcSEcCtD
Mirabegron—Infestation NOS—Doxorubicin—pancreatic cancer	0.000311	0.00155	CcSEcCtD
Mirabegron—Infestation—Doxorubicin—pancreatic cancer	0.000311	0.00155	CcSEcCtD
Mirabegron—Tachycardia—Docetaxel—pancreatic cancer	0.000311	0.00154	CcSEcCtD
Mirabegron—Skin disorder—Docetaxel—pancreatic cancer	0.000309	0.00154	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000309	0.00153	CcSEcCtD
Mirabegron—Diarrhoea—Gemcitabine—pancreatic cancer	0.000307	0.00152	CcSEcCtD
Mirabegron—Dizziness—Irinotecan—pancreatic cancer	0.000304	0.00151	CcSEcCtD
Mirabegron—Rhinitis—Epirubicin—pancreatic cancer	0.000303	0.0015	CcSEcCtD
Mirabegron—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000303	0.0015	CcSEcCtD
Mirabegron—Diarrhoea—Fluorouracil—pancreatic cancer	0.000302	0.0015	CcSEcCtD
Mirabegron—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000298	0.00148	CcSEcCtD
Mirabegron—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000297	0.00147	CcSEcCtD
Mirabegron—Urethral disorder—Epirubicin—pancreatic cancer	0.000296	0.00147	CcSEcCtD
Mirabegron—Sinusitis—Doxorubicin—pancreatic cancer	0.000292	0.00145	CcSEcCtD
Mirabegron—Dizziness—Fluorouracil—pancreatic cancer	0.000291	0.00145	CcSEcCtD
Mirabegron—Rash—Irinotecan—pancreatic cancer	0.00029	0.00144	CcSEcCtD
Mirabegron—Dermatitis—Irinotecan—pancreatic cancer	0.00029	0.00144	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.00029	0.00144	CcSEcCtD
Mirabegron—Headache—Irinotecan—pancreatic cancer	0.000288	0.00143	CcSEcCtD
Mirabegron—Erythema multiforme—Epirubicin—pancreatic cancer	0.000286	0.00142	CcSEcCtD
Mirabegron—Rash—Gemcitabine—pancreatic cancer	0.000283	0.0014	CcSEcCtD
Mirabegron—Dermatitis—Gemcitabine—pancreatic cancer	0.000282	0.0014	CcSEcCtD
Mirabegron—Eye disorder—Epirubicin—pancreatic cancer	0.000282	0.0014	CcSEcCtD
Mirabegron—Headache—Gemcitabine—pancreatic cancer	0.000281	0.0014	CcSEcCtD
Mirabegron—Cardiac disorder—Epirubicin—pancreatic cancer	0.00028	0.00139	CcSEcCtD
Mirabegron—Rhinitis—Doxorubicin—pancreatic cancer	0.00028	0.00139	CcSEcCtD
Mirabegron—Dyspepsia—Docetaxel—pancreatic cancer	0.00028	0.00139	CcSEcCtD
Mirabegron—Rash—Fluorouracil—pancreatic cancer	0.000278	0.00138	CcSEcCtD
Mirabegron—Dermatitis—Fluorouracil—pancreatic cancer	0.000278	0.00138	CcSEcCtD
Mirabegron—Headache—Fluorouracil—pancreatic cancer	0.000276	0.00137	CcSEcCtD
Mirabegron—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000276	0.00137	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000275	0.00136	CcSEcCtD
Mirabegron—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000275	0.00136	CcSEcCtD
Mirabegron—Fatigue—Docetaxel—pancreatic cancer	0.000274	0.00136	CcSEcCtD
Mirabegron—Urethral disorder—Doxorubicin—pancreatic cancer	0.000274	0.00136	CcSEcCtD
Mirabegron—Nausea—Irinotecan—pancreatic cancer	0.000273	0.00136	CcSEcCtD
Mirabegron—Constipation—Docetaxel—pancreatic cancer	0.000272	0.00135	CcSEcCtD
Mirabegron—Nausea—Gemcitabine—pancreatic cancer	0.000266	0.00132	CcSEcCtD
Mirabegron—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000264	0.00131	CcSEcCtD
Mirabegron—Nausea—Fluorouracil—pancreatic cancer	0.000262	0.0013	CcSEcCtD
Mirabegron—Eye disorder—Doxorubicin—pancreatic cancer	0.000261	0.0013	CcSEcCtD
Mirabegron—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00026	0.00129	CcSEcCtD
Mirabegron—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000259	0.00129	CcSEcCtD
Mirabegron—Back pain—Epirubicin—pancreatic cancer	0.000254	0.00126	CcSEcCtD
Mirabegron—Abdominal pain—Docetaxel—pancreatic cancer	0.000252	0.00125	CcSEcCtD
Mirabegron—Vision blurred—Epirubicin—pancreatic cancer	0.000248	0.00123	CcSEcCtD
Mirabegron—Back pain—Doxorubicin—pancreatic cancer	0.000235	0.00117	CcSEcCtD
Mirabegron—Palpitations—Epirubicin—pancreatic cancer	0.000232	0.00115	CcSEcCtD
Mirabegron—Vision blurred—Doxorubicin—pancreatic cancer	0.000229	0.00114	CcSEcCtD
Mirabegron—Asthenia—Docetaxel—pancreatic cancer	0.000228	0.00113	CcSEcCtD
Mirabegron—Hypertension—Epirubicin—pancreatic cancer	0.000227	0.00113	CcSEcCtD
Mirabegron—Pruritus—Docetaxel—pancreatic cancer	0.000225	0.00112	CcSEcCtD
Mirabegron—Arthralgia—Epirubicin—pancreatic cancer	0.000224	0.00111	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000222	0.0011	CcSEcCtD
Mirabegron—Dry mouth—Epirubicin—pancreatic cancer	0.000219	0.00109	CcSEcCtD
Mirabegron—Diarrhoea—Docetaxel—pancreatic cancer	0.000218	0.00108	CcSEcCtD
Mirabegron—Palpitations—Doxorubicin—pancreatic cancer	0.000215	0.00107	CcSEcCtD
Mirabegron—Infection—Epirubicin—pancreatic cancer	0.000213	0.00106	CcSEcCtD
Mirabegron—Dizziness—Docetaxel—pancreatic cancer	0.00021	0.00105	CcSEcCtD
Mirabegron—Hypertension—Doxorubicin—pancreatic cancer	0.00021	0.00104	CcSEcCtD
Mirabegron—ORM1—gall bladder—pancreatic cancer	0.00021	0.146	CbGeAlD
Mirabegron—Tachycardia—Epirubicin—pancreatic cancer	0.000209	0.00104	CcSEcCtD
Mirabegron—Skin disorder—Epirubicin—pancreatic cancer	0.000208	0.00104	CcSEcCtD
Mirabegron—Arthralgia—Doxorubicin—pancreatic cancer	0.000207	0.00103	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000206	0.00102	CcSEcCtD
Mirabegron—Dry mouth—Doxorubicin—pancreatic cancer	0.000203	0.00101	CcSEcCtD
Mirabegron—Rash—Docetaxel—pancreatic cancer	0.000201	0.000997	CcSEcCtD
Mirabegron—Dermatitis—Docetaxel—pancreatic cancer	0.0002	0.000996	CcSEcCtD
Mirabegron—Headache—Docetaxel—pancreatic cancer	0.000199	0.00099	CcSEcCtD
Mirabegron—Infection—Doxorubicin—pancreatic cancer	0.000197	0.00098	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000196	0.000971	CcSEcCtD
Mirabegron—Tachycardia—Doxorubicin—pancreatic cancer	0.000194	0.000963	CcSEcCtD
Mirabegron—Skin disorder—Doxorubicin—pancreatic cancer	0.000193	0.000958	CcSEcCtD
Mirabegron—Nausea—Docetaxel—pancreatic cancer	0.000189	0.000939	CcSEcCtD
Mirabegron—Dyspepsia—Epirubicin—pancreatic cancer	0.000189	0.000939	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000185	0.000921	CcSEcCtD
Mirabegron—Fatigue—Epirubicin—pancreatic cancer	0.000185	0.000919	CcSEcCtD
Mirabegron—ALB—gall bladder—pancreatic cancer	0.000184	0.128	CbGeAlD
Mirabegron—Constipation—Epirubicin—pancreatic cancer	0.000184	0.000912	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000181	0.000899	CcSEcCtD
Mirabegron—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000175	0.000872	CcSEcCtD
Mirabegron—Dyspepsia—Doxorubicin—pancreatic cancer	0.000175	0.000868	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000171	0.000852	CcSEcCtD
Mirabegron—Fatigue—Doxorubicin—pancreatic cancer	0.000171	0.000851	CcSEcCtD
Mirabegron—Urticaria—Epirubicin—pancreatic cancer	0.00017	0.000847	CcSEcCtD
Mirabegron—Constipation—Doxorubicin—pancreatic cancer	0.00017	0.000844	CcSEcCtD
Mirabegron—Abdominal pain—Epirubicin—pancreatic cancer	0.00017	0.000843	CcSEcCtD
Mirabegron—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000162	0.000807	CcSEcCtD
Mirabegron—Urticaria—Doxorubicin—pancreatic cancer	0.000158	0.000784	CcSEcCtD
Mirabegron—Abdominal pain—Doxorubicin—pancreatic cancer	0.000157	0.00078	CcSEcCtD
Mirabegron—Asthenia—Epirubicin—pancreatic cancer	0.000154	0.000765	CcSEcCtD
Mirabegron—Pruritus—Epirubicin—pancreatic cancer	0.000152	0.000754	CcSEcCtD
Mirabegron—Diarrhoea—Epirubicin—pancreatic cancer	0.000147	0.00073	CcSEcCtD
Mirabegron—Asthenia—Doxorubicin—pancreatic cancer	0.000142	0.000708	CcSEcCtD
Mirabegron—Dizziness—Epirubicin—pancreatic cancer	0.000142	0.000705	CcSEcCtD
Mirabegron—Pruritus—Doxorubicin—pancreatic cancer	0.00014	0.000698	CcSEcCtD
Mirabegron—Diarrhoea—Doxorubicin—pancreatic cancer	0.000136	0.000675	CcSEcCtD
Mirabegron—Rash—Epirubicin—pancreatic cancer	0.000135	0.000672	CcSEcCtD
Mirabegron—Dermatitis—Epirubicin—pancreatic cancer	0.000135	0.000672	CcSEcCtD
Mirabegron—Headache—Epirubicin—pancreatic cancer	0.000134	0.000668	CcSEcCtD
Mirabegron—Dizziness—Doxorubicin—pancreatic cancer	0.000131	0.000652	CcSEcCtD
Mirabegron—Nausea—Epirubicin—pancreatic cancer	0.000127	0.000633	CcSEcCtD
Mirabegron—Rash—Doxorubicin—pancreatic cancer	0.000125	0.000622	CcSEcCtD
Mirabegron—Dermatitis—Doxorubicin—pancreatic cancer	0.000125	0.000621	CcSEcCtD
Mirabegron—Headache—Doxorubicin—pancreatic cancer	0.000124	0.000618	CcSEcCtD
Mirabegron—Nausea—Doxorubicin—pancreatic cancer	0.000118	0.000586	CcSEcCtD
Mirabegron—SLCO1A2—digestive system—pancreatic cancer	7.28e-05	0.0507	CbGeAlD
Mirabegron—BCHE—digestive system—pancreatic cancer	5.12e-05	0.0357	CbGeAlD
Mirabegron—ABCB1—islet of Langerhans—pancreatic cancer	4.06e-05	0.0283	CbGeAlD
Mirabegron—CYP3A4—digestive system—pancreatic cancer	3.45e-05	0.024	CbGeAlD
Mirabegron—CYP2D6—digestive system—pancreatic cancer	3.39e-05	0.0236	CbGeAlD
Mirabegron—ABCB1—pancreas—pancreatic cancer	2.86e-05	0.0199	CbGeAlD
Mirabegron—ABCB1—digestive system—pancreatic cancer	2.44e-05	0.017	CbGeAlD
Mirabegron—ADRB3—Signaling Pathways—CCKAR—pancreatic cancer	2.06e-05	0.00132	CbGpPWpGaD
Mirabegron—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—pancreatic cancer	2.05e-05	0.00131	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—JAG2—pancreatic cancer	2e-05	0.00128	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MEN1—pancreatic cancer	1.97e-05	0.00126	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—TYMP—pancreatic cancer	1.97e-05	0.00126	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—TGFB1—pancreatic cancer	1.91e-05	0.00122	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—SHH—pancreatic cancer	1.88e-05	0.0012	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—NOTCH4—pancreatic cancer	1.87e-05	0.0012	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—TNF—pancreatic cancer	1.86e-05	0.00119	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IAPP—pancreatic cancer	1.86e-05	0.00119	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.85e-05	0.00119	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GLP1R—pancreatic cancer	1.81e-05	0.00116	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PTHLH—pancreatic cancer	1.78e-05	0.00114	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PTCH1—pancreatic cancer	1.78e-05	0.00114	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—DPYD—pancreatic cancer	1.78e-05	0.00114	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—TNF—pancreatic cancer	1.78e-05	0.00114	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	1.77e-05	0.00113	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	1.76e-05	0.00113	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—PIK3CG—pancreatic cancer	1.74e-05	0.00111	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—EGF—pancreatic cancer	1.72e-05	0.0011	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	1.69e-05	0.00108	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—SLC2A2—pancreatic cancer	1.69e-05	0.00108	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.67e-05	0.00107	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—SST—pancreatic cancer	1.63e-05	0.00104	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.62e-05	0.00104	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.61e-05	0.00103	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—PIK3CG—pancreatic cancer	1.61e-05	0.00103	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—JAG1—pancreatic cancer	1.6e-05	0.00102	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—NOTCH3—pancreatic cancer	1.59e-05	0.00102	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GLP1R—pancreatic cancer	1.59e-05	0.00102	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—CD44—pancreatic cancer	1.58e-05	0.00101	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—DPYD—pancreatic cancer	1.56e-05	0.000999	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	1.54e-05	0.000988	CbGpPWpGaD
Mirabegron—ABCB1—HIF-1-alpha transcription factor network—AKT1—pancreatic cancer	1.53e-05	0.000979	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—PIK3CD—pancreatic cancer	1.53e-05	0.000979	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—IFNA1—pancreatic cancer	1.53e-05	0.000977	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CNR1—pancreatic cancer	1.51e-05	0.000964	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—SLC2A2—pancreatic cancer	1.48e-05	0.000948	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.47e-05	0.00094	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.47e-05	0.000939	CbGpPWpGaD
Mirabegron—BCHE—Transmission across Chemical Synapses—HRAS—pancreatic cancer	1.46e-05	0.000936	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—PIK3CG—pancreatic cancer	1.46e-05	0.000936	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—GCG—pancreatic cancer	1.45e-05	0.000931	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PRSS1—pancreatic cancer	1.45e-05	0.000926	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—IFNA2—pancreatic cancer	1.42e-05	0.000909	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.41e-05	0.000906	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—PIK3CD—pancreatic cancer	1.41e-05	0.000906	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—AGTR1—pancreatic cancer	1.39e-05	0.000888	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—STK11—pancreatic cancer	1.37e-05	0.000875	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—PIK3CB—pancreatic cancer	1.33e-05	0.000853	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—CD44—pancreatic cancer	1.31e-05	0.000837	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	1.3e-05	0.000833	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.29e-05	0.000825	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—PIK3CD—pancreatic cancer	1.28e-05	0.000822	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.28e-05	0.00082	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.27e-05	0.000812	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PRSS1—pancreatic cancer	1.27e-05	0.000811	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ARG2—pancreatic cancer	1.25e-05	0.000803	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GCG—pancreatic cancer	1.25e-05	0.000803	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.23e-05	0.000789	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	1.21e-05	0.000773	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—SMAD4—pancreatic cancer	1.2e-05	0.000767	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PRSS1—pancreatic cancer	1.19e-05	0.000765	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—CXCL8—pancreatic cancer	1.18e-05	0.000759	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—STK11—pancreatic cancer	1.18e-05	0.000755	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	1.17e-05	0.000752	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—HES1—pancreatic cancer	1.17e-05	0.000749	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	1.16e-05	0.000745	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—CD44—pancreatic cancer	1.15e-05	0.000734	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	1.13e-05	0.000726	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.12e-05	0.000719	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—MMP2—pancreatic cancer	1.12e-05	0.000719	CbGpPWpGaD
Mirabegron—BCHE—Neuronal System—HRAS—pancreatic cancer	1.12e-05	0.000717	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—PIK3CB—pancreatic cancer	1.12e-05	0.000717	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.11e-05	0.000713	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.11e-05	0.000708	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GCG—pancreatic cancer	1.1e-05	0.000704	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ARG2—pancreatic cancer	1.1e-05	0.000704	CbGpPWpGaD
Mirabegron—ALB—Metabolism—TYMP—pancreatic cancer	1.1e-05	0.000702	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CXCL8—pancreatic cancer	1.08e-05	0.000689	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	1.07e-05	0.000684	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	1.05e-05	0.000673	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	1.04e-05	0.000666	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ARG2—pancreatic cancer	1.04e-05	0.000663	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—STK11—pancreatic cancer	1.03e-05	0.000662	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TERT—pancreatic cancer	1.02e-05	0.000656	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	1.02e-05	0.000656	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—TYMS—pancreatic cancer	1.01e-05	0.000649	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PLAU—pancreatic cancer	1.01e-05	0.000645	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—HIF1A—pancreatic cancer	9.8e-06	0.000627	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TSC2—pancreatic cancer	9.77e-06	0.000626	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	9.71e-06	0.000621	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—TYMP—pancreatic cancer	9.6e-06	0.000615	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—APOE—pancreatic cancer	9.56e-06	0.000612	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	9.55e-06	0.000611	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	9.42e-06	0.000603	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	9.4e-06	0.000602	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—KDR—pancreatic cancer	9.37e-06	0.0006	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—CXCL8—pancreatic cancer	9.33e-06	0.000597	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	9.22e-06	0.00059	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—TYMP—pancreatic cancer	9.05e-06	0.000579	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	9.04e-06	0.000579	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PIK3CG—pancreatic cancer	8.97e-06	0.000574	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—NFKBIA—pancreatic cancer	8.91e-06	0.000571	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—TYMS—pancreatic cancer	8.89e-06	0.000569	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—EGF—pancreatic cancer	8.86e-06	0.000567	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GLP1R—pancreatic cancer	8.84e-06	0.000566	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—NOTCH1—pancreatic cancer	8.83e-06	0.000565	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	8.78e-06	0.000562	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	8.71e-06	0.000558	CbGpPWpGaD
Mirabegron—ALB—Metabolism—DPYD—pancreatic cancer	8.69e-06	0.000557	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PIK3CG—pancreatic cancer	8.63e-06	0.000553	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—NRAS—pancreatic cancer	8.63e-06	0.000553	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—CTNNB1—pancreatic cancer	8.6e-06	0.000551	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—EGF—pancreatic cancer	8.53e-06	0.000546	CbGpPWpGaD
Mirabegron—ALB—Metabolism—SLC2A2—pancreatic cancer	8.25e-06	0.000528	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—APOE—pancreatic cancer	8.24e-06	0.000528	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	8.16e-06	0.000523	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	8.13e-06	0.00052	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	8e-06	0.000512	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PIK3CD—pancreatic cancer	7.88e-06	0.000505	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	7.88e-06	0.000504	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—EGFR—pancreatic cancer	7.86e-06	0.000504	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PRSS1—pancreatic cancer	7.81e-06	0.0005	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	7.8e-06	0.0005	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GLP1R—pancreatic cancer	7.74e-06	0.000496	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	7.74e-06	0.000496	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—DPYD—pancreatic cancer	7.62e-06	0.000488	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PIK3CD—pancreatic cancer	7.59e-06	0.000486	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.52e-06	0.000481	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CG—pancreatic cancer	7.44e-06	0.000476	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—KRAS—pancreatic cancer	7.43e-06	0.000476	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GLP1R—pancreatic cancer	7.29e-06	0.000467	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—APOE—pancreatic cancer	7.23e-06	0.000463	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—SLC2A2—pancreatic cancer	7.23e-06	0.000463	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PPARG—pancreatic cancer	7.18e-06	0.00046	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—DPYD—pancreatic cancer	7.18e-06	0.00046	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	7.18e-06	0.000459	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PIK3CB—pancreatic cancer	6.87e-06	0.00044	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.85e-06	0.000438	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—PIK3CA—pancreatic cancer	6.83e-06	0.000437	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	6.81e-06	0.000436	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ARG2—pancreatic cancer	6.77e-06	0.000433	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	6.64e-06	0.000425	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PIK3CB—pancreatic cancer	6.61e-06	0.000423	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CD—pancreatic cancer	6.54e-06	0.000419	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	6.54e-06	0.000418	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CG—pancreatic cancer	6.53e-06	0.000418	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CD44—pancreatic cancer	6.39e-06	0.000409	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CXCL8—pancreatic cancer	6.36e-06	0.000407	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—HRAS—pancreatic cancer	6.31e-06	0.000404	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PPARG—pancreatic cancer	6.3e-06	0.000403	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	6.25e-06	0.0004	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	6.2e-06	0.000397	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—AKT1—pancreatic cancer	6.14e-06	0.000393	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GCG—pancreatic cancer	6.12e-06	0.000392	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CASP3—pancreatic cancer	6.08e-06	0.00039	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CCND1—pancreatic cancer	5.92e-06	0.000379	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—TYMP—pancreatic cancer	5.92e-06	0.000379	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CTNNB1—pancreatic cancer	5.86e-06	0.000375	CbGpPWpGaD
Mirabegron—ALB—Metabolism—STK11—pancreatic cancer	5.76e-06	0.000369	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MMP9—pancreatic cancer	5.75e-06	0.000368	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CD—pancreatic cancer	5.74e-06	0.000367	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PTEN—pancreatic cancer	5.72e-06	0.000366	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CB—pancreatic cancer	5.7e-06	0.000365	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PTGS2—pancreatic cancer	5.65e-06	0.000362	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CD44—pancreatic cancer	5.6e-06	0.000358	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—AKT1—pancreatic cancer	5.58e-06	0.000357	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—SRC—pancreatic cancer	5.51e-06	0.000353	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.4e-06	0.000346	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GCG—pancreatic cancer	5.37e-06	0.000344	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—VEGFA—pancreatic cancer	5.36e-06	0.000343	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—SRC—pancreatic cancer	5.3e-06	0.000339	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—NRAS—pancreatic cancer	5.3e-06	0.000339	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CD44—pancreatic cancer	5.27e-06	0.000338	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—VEGFA—pancreatic cancer	5.16e-06	0.000331	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—STAT3—pancreatic cancer	5.11e-06	0.000327	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—NRAS—pancreatic cancer	5.1e-06	0.000326	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GCG—pancreatic cancer	5.06e-06	0.000324	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—STK11—pancreatic cancer	5.04e-06	0.000323	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CB—pancreatic cancer	5e-06	0.00032	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PTGS2—pancreatic cancer	4.96e-06	0.000317	CbGpPWpGaD
Mirabegron—ALB—Metabolism—TYMS—pancreatic cancer	4.95e-06	0.000317	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PTEN—pancreatic cancer	4.93e-06	0.000315	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TGFB1—pancreatic cancer	4.92e-06	0.000315	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GLP1R—pancreatic cancer	4.77e-06	0.000305	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—STK11—pancreatic cancer	4.75e-06	0.000304	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MYC—pancreatic cancer	4.75e-06	0.000304	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TGFB1—pancreatic cancer	4.74e-06	0.000303	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—DPYD—pancreatic cancer	4.69e-06	0.0003	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—EGFR—pancreatic cancer	4.65e-06	0.000297	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—KRAS—pancreatic cancer	4.56e-06	0.000292	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	4.45e-06	0.000285	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—KRAS—pancreatic cancer	4.39e-06	0.000281	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—TYMS—pancreatic cancer	4.34e-06	0.000278	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PTEN—pancreatic cancer	4.32e-06	0.000277	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PIK3CA—pancreatic cancer	4.19e-06	0.000268	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—TYMS—pancreatic cancer	4.09e-06	0.000262	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TP53—pancreatic cancer	4.05e-06	0.000259	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PIK3CA—pancreatic cancer	4.03e-06	0.000258	CbGpPWpGaD
Mirabegron—ALB—Metabolism—APOE—pancreatic cancer	4.03e-06	0.000258	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TP53—pancreatic cancer	3.9e-06	0.00025	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—HRAS—pancreatic cancer	3.87e-06	0.000248	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.81e-06	0.000244	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—HRAS—pancreatic cancer	3.73e-06	0.000239	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CG—pancreatic cancer	3.64e-06	0.000233	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—APOE—pancreatic cancer	3.53e-06	0.000226	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PPARG—pancreatic cancer	3.51e-06	0.000225	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CA—pancreatic cancer	3.48e-06	0.000223	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CD44—pancreatic cancer	3.45e-06	0.000221	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—AKT1—pancreatic cancer	3.42e-06	0.000219	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—APOE—pancreatic cancer	3.33e-06	0.000213	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GCG—pancreatic cancer	3.31e-06	0.000212	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—AKT1—pancreatic cancer	3.29e-06	0.000211	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CD—pancreatic cancer	3.2e-06	0.000205	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CG—pancreatic cancer	3.19e-06	0.000204	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—STK11—pancreatic cancer	3.11e-06	0.000199	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PPARG—pancreatic cancer	3.07e-06	0.000197	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CA—pancreatic cancer	3.05e-06	0.000195	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	3e-06	0.000192	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PPARG—pancreatic cancer	2.9e-06	0.000185	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—AKT1—pancreatic cancer	2.84e-06	0.000182	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CD—pancreatic cancer	2.8e-06	0.000179	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CB—pancreatic cancer	2.79e-06	0.000178	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PTGS2—pancreatic cancer	2.76e-06	0.000177	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—TYMS—pancreatic cancer	2.67e-06	0.000171	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	2.64e-06	0.000169	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—AKT1—pancreatic cancer	2.49e-06	0.00016	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CB—pancreatic cancer	2.44e-06	0.000156	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PTGS2—pancreatic cancer	2.42e-06	0.000155	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PTEN—pancreatic cancer	2.41e-06	0.000154	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	2.3e-06	0.000147	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PTGS2—pancreatic cancer	2.28e-06	0.000146	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—APOE—pancreatic cancer	2.17e-06	0.000139	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PTEN—pancreatic cancer	2.11e-06	0.000135	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PTEN—pancreatic cancer	1.99e-06	0.000127	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.96e-06	0.000126	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.89e-06	0.000121	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.73e-06	0.00011	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CA—pancreatic cancer	1.7e-06	0.000109	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.5e-06	9.63e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.49e-06	9.54e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CA—pancreatic cancer	1.49e-06	9.53e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.4e-06	8.98e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—AKT1—pancreatic cancer	1.39e-06	8.88e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.3e-06	8.32e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—AKT1—pancreatic cancer	1.22e-06	7.78e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.15e-06	7.33e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	9.17e-07	5.87e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—AKT1—pancreatic cancer	7.49e-07	4.79e-05	CbGpPWpGaD
